British pharmaceutical giant “Corona Vaccine To Be Supplied” Clinical Trial Results May 22 18:14
British pharmaceutical giant AstraZeneca has announced that it is ready to start supplying the new coronavirus vaccine, which is being developed with Oxford University, in September. On the other hand, the results of clinical trials have not yet been produced, and AstraZeneca says development may not work.
According to the announcement, AstraZeneca said it would be able to produce 1 billion doses of the vaccine, which is being developed with Oxford University, next year, and will begin supplying at least 400 million times in September. Of these, 100 million times will be supplied to the UK.
AstraZeneca has received more than $1 billion in support from the U.S. Department of Biomedical Research and Development and more than $107 billion in Japanese yen, british media reported, with about 300 million times being supplied to the United States.
Clinical trials to confirm human safety and efficacy have been conducted since last month, and AstraZeneca says development may not work.
While there are concerns about the development of vaccines for the new coronavirus, astrazeneca says it will work with the WORLD’s World Health Organization and others to ensure that vaccines are passed fairly to the world.